Aminopterin - Syntrix Biosystems

Drug Profile

Aminopterin - Syntrix Biosystems

Alternative Names: Aminotrexate; LD-aminopterin; Rac-aminopterin

Latest Information Update: 05 Feb 2016

Price : $50

At a glance

  • Originator University of Medicine & Dentistry of New Jersey
  • Developer Syntrix Biosystems
  • Class Benzamides; Glutamates; Pterins; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Psoriasis
  • No development reported Acute lymphoblastic leukaemia; Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Aug 2015 Phase-II development is ongoing for Psoriasis and Rheumatoid arthritis
  • 03 Aug 2015 No recent reports on development identified - Phase-II for Acute lymphoblastic leukaemia (In children, In adults) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top